Review of the MMSE as a Pre‐Screening Tool for Dementia in Clinical Trials
Based on this limited analysis, it appears that using the MMSE alone as a screener for dementia may result in missing up to 33% of symptomatic patients. Within these sample groups, the initial self-endorsement of memory concerns was a more reliable predictor of CDR outcomes than the MMSE.
Authors
- Charlotte Jones (ORCID: https://orcid.org/0000-0002-6322-1551)
- Shane Thomas (ORCID: https://orcid.org/0000-0003-3116-6022)
- Pamela Voccia
- Noel Fundora
- Andrew Boateng‐Poku
- Olumide Otekalu
Institutions
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.090910
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00